A nonpathogenic ECN strain was also genetically modified to specifically release CD47 nanoantibody antagonists (CD47 nb) in the tumor microenvironment, increasing the viability of tumor‐infiltrating T‐cells and promoting rapid tumor regression [53]. This evidence concerns the gene CD47 and neoplasm.